Leukemia Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
4186 Etiology Of Alkylator-Induced Myeloid Leukemia
Select
6492
Select
16139B A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes.
Select
16840A E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
09-130-B A University of Chicago Leukemia Registry Protocol.
10-064-B Molecular characterization of hematopoietic malignancies
Select
10-583-A AML08: A Phase III Randomized Trial of Clofarabine, Plus Cytarabine Versus Conventional Induction Therapy and a Phase III Study of Natural Killer Cell Transplantation in Patients With Newly Diangosed Acute Myeloid Leukemia
Select
10-617-A COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
11-0014 Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
Select
11-0650 An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
Select
12-0111 Phase I investigation of the feasibility of combining 5-azacytidine with highdose cytarabine (HiDAC) and mitoxantrone chemotherapy in a sequential manner for remission induction in high-risk acute myelogenous leukemia (AML)
Select
12-0153 A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
Select
12-2179 A Phase 1/2, Open-label, Dose-escalation, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered NS-018 in Patients with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis
Select
12-1959 Initial Phase 1 Study of WT2725 Dosing Emulsion in Patients with Advanced Malignancies
IRB13-0716 Monitoring tyrosine kinase inhibitors (TKI) response in chronic myeloid leukemia (CML) patients by longitudinal collection and evaluation of 'omics' data
Select
12-2245 An Open-label Extension Study in Patients 65 Years or Older with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 versus Chlorambucil)
Select
IRB13-0704 M13-982 - A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
Select
IRB13-0405 CAMN107AUS37A - Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib (Tasigna)
Select
IRB13-0858 A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (ERYASP) in Combination with the CALGB Regimen During Induction and Consolidation Phases for Frontline Therapy of Subjects Older than 40 Years with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
Select
IRB14-0076 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Select
IRB14-0059 A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Select
IRB14-0119 A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) Versus Specified Physician’s Choice in Patients = 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Select
IRB14-0331 A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents
Select
IRB14-0651 A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy
IRB14-1076 Phase I Study of an Oncofetal Antigen (“OFA”) Multi-Peptide Immunotherapy (“BB-MPI-03”) in Subjects with Hematologic Cancer
IRB14-0702 A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)
Select
IRB14-0471 An Open Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/ Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Select
IRB14-0881 A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia with 17p Deletion

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.